Volume 30, Number 4—April 2024
CME ACTIVITY - Synopsis
Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox, Florida, USA, 2021–2022
Table 2
Description of outbreak-related cases during concurrent outbreaks of hepatitis A, invasive meningococcal disease, and mpox, Florida, USA, 2021–2022*
| Characteristics | Value |
||
|---|---|---|---|
| Hepatitis A | Invasive meningococcal disease | Mpox† | |
| Total no. |
153 |
44 |
2,845 |
| Median age, y (range) |
35 (9–75) |
32 (8–77) |
36 (0–81) |
| Race or ethnicity | |||
| White | 102/153 (67) | 29/44 (66) | 1,957/2,845 (69) |
| Hispanic |
53/150 (35) |
22/44 (50) |
1,270/2,845 (45) |
| Sex | |||
| M | 145/153 (95) | 36/44 (82) | 2,786/2,845 (98) |
| F | 8/153 (5) | 8/44 (18) | 59/2,845 (2) |
| Transgender |
4/153 (3) |
1/44 (2) |
22/2,845 (1) |
| MSM‡ |
113/152 (74) |
31/43 (72) |
2,507/2,836 (88) |
| No. sexual partners during past 3 mo‡ | |||
| 0 | 25/100 (25) | 4/31 (13) | 27/1,680 (2)§ |
| 1 | 44/100 (44) | 17/31 (55) | 914/1,680 (54)§ |
| 2–5 | 23/100 (23) | 8/31 (26) | 631/1,680 (38)§ |
| >5 |
8/100 (8) |
2/31 (6) |
108/1,680 (6)§ |
| Sex with unknown person in previous 3 mo‡ |
22/101 (22) |
6/30 (20) |
225/956 (23)§ |
| HIV positive |
32/153 (21) |
14/44 (34) |
1,473/2,836 (52) |
| Taking HIV preexposure prophylaxis |
20/130 (15) |
5/44 (11) |
Unknown |
| STI in previous 2 y |
42/153 (27) |
9/44 (20) |
1,567/2,836 (55) |
| Mpox virus infection in 2022 |
4 |
3 |
All |
| Recent international travel |
12/153 (8) |
1/44 (2) |
199/2,845 (7) |
| Recent homelessness |
8/153 (5) |
2/44 (5) |
25/928 (3) |
| Recent incarceration |
1/153 (<1) |
0/44 (0) |
1/928 (<1) |
| Recent injection drug use |
3/153 (2) |
2/44 (5) |
Unknown |
| Orange County resident |
53/153 (35) |
15/44 (34) |
295/2,845 (10) |
| Food employee |
17/121 (15) |
7/44 (16) |
Unknown |
| Hospitalized |
119/153 (78) |
41/44 (93) |
162/2,845 (6) |
| Died |
1/153 (<1) |
9/44 (20) |
3/2,845 (<1) |
| Outbreak case classification | |||
| Confirmed | 67/153 (44) | 40/44 (91) | 1,720/2,845 (60) |
| Probable | 73/153 (48) | 4/44 (9) | 1,125/2,845 (40) |
| Suspect |
13/153 (8) |
NA |
NA |
| Laboratory evidence of infection with outbreak genotype/sequence | 60/153 (39) | 34/44 (77) | NA |
*Values are no. cases/no. reported (%) except as indicated. All risk factor questions relate to exposures in the 3 mo before symptom onset, except sexual history for mpox cases, which refers to the 3 weeks before symptom onset. Denominators vary based on available data for each variable. Percentages may not add to 100 due to rounding. MSM, men who have sex with men. †Outbreak ongoing, data through November 30, 2022. ‡Minors age <18 y excluded from numerator and denominator. §Number of sexual partners in 3 weeks before onset (mpox incubation period).
1Members of the team are listed at the end of the article.